Diagnostic value of CNV in CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, GSTM1, GSTP1 and GSTT1 for prediction of optimal response and failure of TKI therapy in CML patients (P = 0.0001). Here, CYP2C19 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.